Table 1: Characteristics of patients.
| Number of patients (%) | |
| Total | 63 |
| Median age, years (range) | 64 (40-80) |
| Hormone receptor status | |
| ER-positive and/or PgR-positive | 35 (56%) |
| ER-negative and PgR-negative | 28 (44%) |
| HER2 status | |
| IHC 3+ | 56 (89%) |
| IHC 2+ and ISH positive | 7 (11%) |
| Stage IV | 18 (29%) |
| Recurrence | 45 (71%) |
| Median disease free interval, months (range) | 29 (2-104) |
| < 2 years | 19 (42%) |
| 2-5 years | 19 (42%) |
| ≥ 5 years | 7 (16%) |
| Site of disease involvement | |
| Visceral | 43 (67%) |
| Nonvisceral | 21 (33%) |
| Metastatic site | |
| Lung | 28 (44%) |
| Liver | 21 (33%) |
| Bone | 25 (40%) |
| Brain | 14 (22%) |
| Lymph node | 31 (49%) |
| Other | 30 (48%) |
IHC: immunohistochemistry; ISH: in situ hybridization.